Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (761)	3/26/2007 6:28:49 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 824

Hi Wilder, I appreciate the reaction to the pricing. I think we can be sure it will not get the same reimbursement in EU. >>I could easily see NICE now saying 'only for t-denpendent pts and then 6-months on 6-months off ... I think you are talking about the PNH patients that are transfusion dependent. Well, that would be all the moderate and severe cases as I understand it. As I understand it, it can take 3 or 4 hours just to infuse* 1 unit of blood and all day for two. (Not talking here about trauma cases where the patient is bleeding out and they have to push it in as fast as it is bleeding.) With those kind of numbers it is no wonder these poor folks have a ugly QOL score. >> even a modest co-pay going to be a problem that alxn will eventually eat True. But assume you do not object to this profiteer eating the copay, at least in the sense that it reduces the price of Soliris for some. :-) It does defeat the purpose of having a copay - a sham, futile. I thought I would be really happy to see Soliris launch. Part of me still is and part of me is dismayed. ij * Typing, reaction checking the donor blood vs. proposed infusion unit, infusion, and an hour wait time to see make sure there is no reaction.

To: keokalani'nui who wrote (761)	3/26/2007 9:26:17 PM
From: Robohogs	Read Replies (2) \| Respond to of 824

2 thoughts - First, the cap on many medical plans is $1-2 MM USD (mine is 2) - that drug if needed would kill overall healthcare plan benefit. Use it and nothing else covered. How can they possibly think they are doing the right thing? Second, what do insurance companies do if the co-pay is not really met (i.e., refunded by the drug seller)? Seems this could be problematic as it could lead to price set at any level with no effective co-pay. I am assuming once drug company gets involved, insurance is no longer good and drug company gets ZERO revenue. Anyone know? Jon